Aesthetic plastic surgery · 2026
Polynucleotide (PN) Therapy for Accelerated Wound Repair and Scar Modulation in Aesthetic Procedures.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Soo-Yeon, Kim Michael, Yoon Song-Eun, Song Jong-Keun, Sloane Jake, Green Jeremy B, Rappl Thomas, Kim Jin-Hyun, Yi Kyu-Ho
Аннотация
BACKGROUND: Postoperative wound compromise after aesthetic procedures may manifest as delayed epithelialization, tissue ischemia, hypertrophic scarring, contour depression, or wound dehiscence. These problems are more common in patients with impaired microcirculation or other healing-related comorbidities.
OBJECTIVES: To describe the clinical use of injectable polynucleotide as an adjunctive treatment for postoperative wound healing and scar modulation after aesthetic procedures.
METHODS: This retrospective case series included eight consecutive patients treated in routine practice at a single aesthetic clinic over a continuous study accrual period. Eligible patients had clinically significant wound healing delay, early ischemic change, hypertrophic scarring, or postoperative contour depression after aesthetic surgery or facial trauma and were managed with injectable polynucleotide (Rejuran). Treatments were individualized according to wound status and tissue quality, typically using 1-2 mL per session at 2- to 3-week intervals. Because of the heterogeneous case mix and retrospective design, outcomes were evaluated by serial standardized clinical photographs and physician-rated changes in wound size, erythema, scar width/elevation, and contour rather than by a single validated scar scale.
RESULTS: All eight patients demonstrated clinical improvement after treatment, including faster re-epithelialization, reduction of erythema, narrowing and flattening of scars, improved contour, or complete wound closure. Earlier treatment during the inflammatory or early proliferative phase appeared to produce the most favorable results. No treatment-related adverse events were documented.
CONCLUSIONS: The application of injectable polynucleotide therapy appears to be a safe and useful adjunct for postoperative wound care and scar modulation in aesthetic practice. Early use may be especially helpful in patients at high risk for wound breakdown, although prospective studies using standardized outcome measures are needed.
LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
OBJECTIVES: To describe the clinical use of injectable polynucleotide as an adjunctive treatment for postoperative wound healing and scar modulation after aesthetic procedures.
METHODS: This retrospective case series included eight consecutive patients treated in routine practice at a single aesthetic clinic over a continuous study accrual period. Eligible patients had clinically significant wound healing delay, early ischemic change, hypertrophic scarring, or postoperative contour depression after aesthetic surgery or facial trauma and were managed with injectable polynucleotide (Rejuran). Treatments were individualized according to wound status and tissue quality, typically using 1-2 mL per session at 2- to 3-week intervals. Because of the heterogeneous case mix and retrospective design, outcomes were evaluated by serial standardized clinical photographs and physician-rated changes in wound size, erythema, scar width/elevation, and contour rather than by a single validated scar scale.
RESULTS: All eight patients demonstrated clinical improvement after treatment, including faster re-epithelialization, reduction of erythema, narrowing and flattening of scars, improved contour, or complete wound closure. Earlier treatment during the inflammatory or early proliferative phase appeared to produce the most favorable results. No treatment-related adverse events were documented.
CONCLUSIONS: The application of injectable polynucleotide therapy appears to be a safe and useful adjunct for postoperative wound care and scar modulation in aesthetic practice. Early use may be especially helpful in patients at high risk for wound breakdown, although prospective studies using standardized outcome measures are needed.
LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .